MLTX
MoonLake Immunotherapeutics
11.60$
-4.0%
vs. previous close
Closing price · As of: Sep 28, 2026
Statements
Cash Flow
MoonLake Immunotherapeutics (MLTX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (2025), "Operating Cash Flow" came in at -196 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| -0.3 | -35 | -56 | -43 | -117 | -196 | |
| – | 0.0 | 0.2 | 0.4 | 1.4 | 2.6 | |
| – | 11 | 9.7 | 7.1 | 7.3 | 13 | |
| – | -4.5 | 9.7 | – | – | – | |
| -0.2 | 4.5 | -1.6 | -6.2 | -3.8 | 20 | |
| 0.0 | 0.1 | 0.0 | 0.3 | 0.5 | 0.0 | |
| -115 | -0.1 | -32 | -25 | -206 | 203 | |
| – | 0.1 | – | – | – | – | |
| – | 0.0 | 0.0 | 0.0 | 0.0 | – | |
| – | -0.1 | -15 | 0.0 | 0.0 | 73 | |
| 117 | 43 | 120 | 480 | 51 | 146 | |
| 1.3 | 6.7 | 31 | 412 | -271 | 154 | |
| -0.3 | -35 | -56 | -43 | -117 | -196 |
Data as of: September 28, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.